Intellia Therapeutics, Inc.
Intellia Therapeutics is a clinical-stage biopharmaceutical company built around CRISPR-based gene editing and related delivery technologies. It is developing potentially curative therapies for severe genetic diseases, with its lead programs lonvoguran ziclumeran (NTLA-2002) for hereditary angioedema and nexiguran ziclumeran (NTLA-2001) for ATTR amyloidosis in Phase 3 development.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSystemically administered CRISPR-based drug candidates designed to durably edit disease-causing genes in the body.
NTLA-2002 and NTLA-2001, the company's most advanced programs targeting HAE and ATTR amyloidosis.
Oligonucleotide and lipid nanoparticle tools used to enable targeted in vivo gene editing.
Upfront fees, research funding, cost reimbursements, and milestones from strategic partners.
Asiakkaat
Intellia does not yet sell approved medicines directly to patients; its current customers are collaboration partners that pay for access to its technology, research support, and development rights. If its lead programs are approved, the end customers would be specialty physicians and patients with severe genetic diseases such as hereditary angioedema and ATTR amyloidosis.
Regeneron, AvenCell, SparingVision, Kyverna, ONK, and ReCode pay for technology access, research support, and milestone-linked development rights.
Future end users of lonvoguran ziclumeran, a one-time IV gene-editing therapy intended to reduce disease burden and attack frequency.
Future end users of nexiguran ziclumeran, designed to address the root cause of transthyretin amyloid disease.
Prescribers and infusion sites that would adopt and administer approved therapies in outpatient settings.
Strategia
Intellia is focused on advancing its in vivo CRISPR platform through late-stage clinical development and preparing for a planned first commercial launch of lonvo-z in the first half of 2027. Near term, it is prioritizing delivery technology, manufacturing readiness, regulatory execution, and collaboration funding to extend runway and reduce dependence on equity financing.
Clinical success is the main value driver and prerequisite for approval and commercialization.
The company expects a potential first launch in 2027 and must build launch capabilities or partner for them.
Better delivery and editing performance improve probability of success across current and future programs.
Collaboration revenue and reimbursements help fund operations before product sales begin.
Maantiede
Intellia is headquartered in the United States and its business is centered on U.S.-based research, development, and clinical operations. The company also relies on global collaboration and clinical/regulatory pathways, but the filings provided do not disclose a country-by-country revenue split.
Riskit
Intellia faces the core risks of a clinical-stage gene-editing company: unproven technology, lengthy trials, regulatory uncertainty, and dependence on third parties for manufacturing and commercialization. It also has no current sales infrastructure, so even approval would require either building commercial capabilities or securing partners, while ongoing losses and capital needs remain material.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
Lead programs are still in Phase 3, and adverse efficacy or safety data could eliminate commercialization prospects.
Kohdistuu: NTLA-2002 and NTLA-2001
- Unproven CRISPR platformVaikutus: KorkeaTodennäköisyys: Korkea
The company itself notes that CRISPR/Cas9 genome editing has only recently been clinically validated for human use.
Kohdistuu: Platform-wide
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
The business remains loss-making and may need additional capital before product revenue begins.
Kohdistuu: Runway and future funding
- Manufacturing and supply chain dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Clinical and future commercial supply rely on third parties for inputs, quality, and capacity.
Kohdistuu: Drug substance and product supply
- Commercialization execution riskVaikutus: KorkeaTodennäköisyys: Matala
The company has no sales, marketing, or distribution infrastructure and may need to build one or partner.
Kohdistuu: Post-approval launch
Kirjanpito
Harkinnanvaraiset erätRevenue includes upfront access fees, research funding, and milestone payments, so timing depends on contract terms and performance obligations.
Vaikutus: Can create quarter-to-quarter volatility in reported revenue
Clinical trial, manufacturing, and CRO costs are estimated and accrued before invoices are finalized.
Vaikutus: Affects operating expense timing and loss recognition
Equity awards are a significant component of employee compensation in a biotech company.
Vaikutus: Raises operating expenses without immediate cash outflow
Investments and contingent consideration are remeasured, creating non-operating volatility.
Vaikutus: Can affect net loss and other income
Right-of-use assets and lease liabilities can change with remeasurement and facility usage.
Vaikutus: Affects assets, liabilities, and non-cash disclosures
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Lexeo Therapeutics, Inc.
LXEO · Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics is a U.S.-based clinical-stage biotechnology company developing gene therapy candidates for serious cardiovascular and neuromuscular diseases.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Crispr Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
Metagenomi Therapeutics, Inc.
MGX · Biological Products, (No Diagnostic Substances)
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Päivitetty: 24.9.2026